Posters and Presentations :: SCYNEXIS, Inc. (SCYX)

Penetration of Ibrexafungerp (formerly SCY-078) versus Micafungin at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model

Annie Lee, Brendan Prideaux, Min Hee Lee, Matthew Zimmerman, Padmaja Paderua, Stephen A. Barat, David Angulo, David S. Perlin, Yanan Zhao
ASM Microbe 2019
June 2019

Activity of a novel 1,3-beta-D-glucan inhibitor, Ibrexafungerp (formerly SCY-078), against Candida glabrata

M. Ghannoum, L. Long, C. Hager, R. Wilson, K. Borroto-Esoda, S. Barat, and D. Angulo
ASM Microbe 2019
June 2019

Efficacy of Oral Ibrexafungerp (IBX, Formerly SCY-078) in the Treatment of <em>Candida auris</em> Infection in a Murine Disseminated Model

Efficacy of Oral Ibrexafungerp (IBX, Formerly SCY-078) in the Treatment of Candida auris Infection in a Murine Disseminated Model

M. Ghannoum, L. Long, C. Hager, K. Borroto-Esoda, S. Barat, and D. Angulo
ASM Microbe 2019
June 2019

$Interim Analysis of a Phase 3 Open-label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (formerly SCY-078) in Patients with Refractory or Intolerant Fungal Diseases (FURI)$

Interim Analysis of a Phase 3 Open-label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (formerly SCY-078) in Patients with Refractory or Intolerant Fungal Diseases (FURI)

OA Cornely, L Ostrosky-Zeichner, R Miller, A Spec, GR Thompson, TJ Walsh, R Rautemaa-Richardson, R Krause, KM Mullane, PG Pappas, CG
Morse, JW Sanders, G Weiss, O Witzke, J Vazquez, MH Miceli, TF Patterson, M Hoenigl, BD Alexander, DA Angulo
ASM Microbe 2019
June 2019

Ibrexafungerp, a Novel Oral Antifungal, Demonstrates No Reproductive or Developmental Harm in Preclinical Models

C.M. Carruthers, S. Barat, D. Angulo, P. Thomas, E. Lewis, R. Sobel
ACOG 2019
May 2019

A Phase 2b, Dose-Finding Study Evaluating Oral Ibrexafungerp in Vulvovaginal Candidiasis (DOVE)

P. Nyirjesy, R. Cadet, M. Tufa, D. Angulo
ACOG 2019
May 2019

<em>In Vitro</em> Activity of the Novel Agent, Ibrexafungerp (formerly SCY-078) Against <em>Candida</em> spp. (Including Fluconazole- Resistant Isolates) Being Developed for the Treatment of Vulvovaginal Candidiasis

In Vitro Activity of the Novel Agent, Ibrexafungerp (formerly SCY-078) Against Candida spp. (Including Fluconazole- Resistant Isolates) Being Developed for the Treatment of Vulvovaginal Candidiasis

Stephen A. Barat, PhD
ACOG 2019
May 2019

$Oral Ibrexafungerp (SCY-078) in Refractory Fungal Diseases<br><sup>Interim Analysis by Pathogen of a Phase 3 Open-label Study (FURI)</sup>$

Oral Ibrexafungerp (SCY-078) in Refractory Fungal Diseases
^{Interim Analysis by Pathogen of a Phase 3 Open-label Study (FURI)}

Oliver A. Cornely MD, FECMM, FIDSA, FAAM, FACP
Consultant, Infectious Diseases
Director, European Mycology Excellence Center
University Hospital of Cologne
ECCMID 2019
April 2019

Successful Treatment of Two Patients with <em>Candida auris</em> Candidemia with the Investigational Agent, Oral Ibrexafungerp (formerly SCY-078), from the CARES Study

Successful Treatment of Two Patients with Candida auris Candidemia with the Investigational Agent, Oral Ibrexafungerp (formerly SCY-078), from the CARES Study

D Juneja, O Singh, B Tarai, DA Angulo
ECCMID 2019
April 2019

Favourable Clinical Outcome of Two Patients with <em>Candida</em> spp. Spondylodiscitis treated with Oral Ibrexafungerp (formerly SCY-078) from the FURI Study

Favourable Clinical Outcome of Two Patients with Candida spp. Spondylodiscitis treated with Oral Ibrexafungerp (formerly SCY-078) from the FURI Study

Philipp Koehler, Oliver A. Cornerly, David Angulo
ECCMID 2019
April 2019